TY  - GEN
AU  - Pozniak,Anton
AU  - Arribas,Jose R
AU  - Gathe,Joseph
AU  - Gupta,Samir K
AU  - Post,Frank A
AU  - Bloch,Mark
AU  - Avihingsanon,Anchalee
AU  - Crofoot,Gordon
AU  - Benson,Paul
AU  - Lichtenstein,Kenneth
AU  - Ramgopal,Moti
AU  - Chetchotisakd,Ploenchan
AU  - Custodio,Joseph M
AU  - Abram,Michael E
AU  - Wei,Xuelian
AU  - Cheng,Andrew
AU  - McCallister,Scott
AU  - SenGupta,Devi
AU  - Fordyce,Marshall W
TI  - Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study
SN  - 1944-7884
PY  - 2016///0720
KW  - Adult
KW  - Albuminuria
KW  - etiology
KW  - Bone Density
KW  - drug effects
KW  - Cobicistat
KW  - therapeutic use
KW  - Drug Substitution
KW  - Drug Therapy, Combination
KW  - Emtricitabine
KW  - Female
KW  - Glomerular Filtration Rate
KW  - HIV Infections
KW  - complications
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Proteinuria
KW  - Quinolones
KW  - Renal Insufficiency
KW  - Tenofovir
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1097/QAI.0000000000000908
ER  -